DIOVAN
Pronunciation: val-SAR-tan (DYE-oe-van)


What it isAngiotensin II receptor blocker; hypertension, heart failure and post-infarction.
Why this oneHeart-failure outcome data, no cough, and it is the ARB component of sacubitril-valsartan.
What limits itHyperkalemia and the same hemodynamic creatinine rise as an ACE inhibitor. Contraindicated in pregnancy.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults | 80–160 mg QD | 80–320 mg QD | 320 mg QD |
| Hypertension | Peds 1–16 y | 1 mg/kg QD (up to 40 mg) | 1–4 mg/kg QD (up to 160 mg) | 160 mg QD |
| Heart failure | Adults | 40 mg BID | 40–160 mg BID | 160 mg BID |
| Post-myocardial infarction | Adults | 20 mg BID | 20–160 mg BID | 160 mg BID |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Can cause fetal harm; discontinue as soon as pregnancy is detected.
Lactation Breastfeeding is not recommended.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 40 mg | tab | 30 qd | $2.89 | offered |
| 80 mg | tab | 30 qd | $2.46 | offered |
| 160 mg | tab | 30 qd | $3.18 | offered |
| 320 mg | tab | 30 qd | $4.90 | offered |
Available combined with: Sacubitril (in ENTRESTO) · sacubitril / valsartan
Generic entry2014
⚠ BOXED WARNING
Principal riskHyperkalemia and acute kidney injury
Legacy pregnancy categoryD
Defining liabilityHyperkalemia, kidney injury, fetal toxicity and increased lithium exposure.
Open Valsartan in the interactive console ↗
